DICYCLOMINE HYDROCHLORIDE | A040317 | AUROBINDO PHARMA USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petiton from Aurobindo Pharma USA, Inc FDA-2018-P-1892 · 4 docket documents Aurobindo Pharma USA, Inc. filed this citizen petition under Section 505(j) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 10.25(a), 10.30, and 314.93 to request that the FDA designate an alternative reference standard for conducting in vivo bioequivalence studies to support an ANDA applicat | Other | 2018-05-16 | Granted | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0563
per ea
Lowest NADAC/Unit
$0.0563
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 59651072001DICYCLOMINE 20 MG TABLET | $0.0563 | EA | Generic | — | 2026-06-17 |
| 59651072099DICYCLOMINE 20 MG TABLET | $0.0563 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.